{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T10:21:25Z","timestamp":1793701285157,"version":"4.5.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T00:00:00Z","timestamp":1645488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T00:00:00Z","timestamp":1645488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic lymphocytic leukemia (CLL) results in increased susceptibility to infections. T cell dysfunction is not associated with CLL in all patients; therefore, it is important to identify CLL patients with T cell defects. The role of B-cell lymphoma-2 (BCL-2) in CLL has been explored; however, few studies have examined its role in T cells in CLL patients. Herein, we have investigated the regulatory role of BCL-2 in T cells in the CLL tumor microenvironment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The expression of BCL-2 in T cells was evaluated using flow cytometry. The regulatory roles of BCL-2 were investigated using single-cell RNA sequencing (scRNA-seq) and verified using multi-parameter flow cytometry on CD4 and CD8 T cells. The clinical features of BCL-2 expression in T cells in CLL were also explored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We found a significant increase in BCL-2 expression in the T cells of CLL patients (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009266). Single cell RNA sequencing (scRNA-seq) indicated that BCL-2\n                      <jats:sup>+<\/jats:sup>\n                      CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells had the gene signature of increased regulatory T cells (Treg); BCL-2\n                      <jats:sup>+<\/jats:sup>\n                      CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells showed the gene signature of exhausted cytotoxic T lymphocytes (CTL); and increased expression of BCL-2 was associated with T cell activation and cellular adhesion. The results from scRNA-seq were verified in peripheral T cells from 70 patients with CLL, wherein BCL-2\n                      <jats:sup>+<\/jats:sup>\n                      CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells were enriched with Tregs and had higher expression of interleukin-10 and transforming growth factor-\u03b2 than BCL-2\n                      <jats:sup>\u2212<\/jats:sup>\n                      CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells. BCL-2 expression in CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells was associated with exhausted cells (PD-1\n                      <jats:sup>+<\/jats:sup>\n                      Tim-3\n                      <jats:sup>+<\/jats:sup>\n                      ) and weak expression of granzyme B and perforin. T cell\u2013associated cytokine profiling revealed a negative association between BCL-2\n                      <jats:sup>+<\/jats:sup>\n                      T cells and T cell activation. Decreased frequencies and recovery functions of BCL-2\n                      <jats:sup>+<\/jats:sup>\n                      T cells were observed in CLL patients in complete remission after treatment with venetoclax.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>BCL-2 expression in the T cells of CLL patients is associated with immunosuppression via promotion of Treg abundance and CTL exhaustion.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12943-022-01516-w","type":"journal-article","created":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T02:02:49Z","timestamp":1645495369000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["BCL-2 expression promotes immunosuppression in chronic lymphocytic leukemia by enhancing regulatory T cell differentiation and cytotoxic T cell exhaustion"],"prefix":"10.1186","volume":"21","author":[{"given":"Lu","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianfeng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senlin","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuegen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhua","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suo","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sishu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runqiu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8649-5531","authenticated-orcid":false,"given":"Dong-Hua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,22]]},"reference":[{"key":"1516_CR1","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1016\/S0140-6736(18)30422-7","volume":"391","author":"M Hallek","year":"2018","unstructured":"Hallek M, Shanafelt TD, Eichhorst B. Chronic lymphocytic leukaemia. Lancet. 2018;391:1524\u201337.","journal-title":"Lancet."},{"key":"1516_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"1516_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.leukres.2018.08.011","volume":"73","author":"S Yang","year":"2018","unstructured":"Yang S, Gale RP, Shi H, Liu Y, Lai Y, Lu J, et al. Is there an epidemic of chronic lymphocytic leukaemia (CLL) in China? Leuk Res. 2018;73:16\u201320.","journal-title":"Leuk Res"},{"key":"1516_CR4","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1002\/ajh.25595","volume":"94","author":"M Hallek","year":"2019","unstructured":"Hallek M. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. Am J Hematol. 2019;94:1266\u201387.","journal-title":"Am J Hematol"},{"key":"1516_CR5","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1182\/blood-2015-03-567388","volume":"126","author":"F Forconi","year":"2015","unstructured":"Forconi F, Moss P. Perturbation of the normal immune system in patients with CLL. Blood. 2015;126:573\u201381.","journal-title":"Blood."},{"key":"1516_CR6","doi-asserted-by":"publisher","first-page":"562","DOI":"10.3324\/haematol.2016.151100","volume":"102","author":"M Palma","year":"2017","unstructured":"Palma M, Gentilcore G, Heimersson K, Mozaffari F, N\u00e4sman-Glaser B, Young E, et al. T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers. Haematologica. 2017;102:562\u201372.","journal-title":"Haematologica."},{"key":"1516_CR7","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa1315226","volume":"370","author":"RR Furman","year":"2014","unstructured":"Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370:997\u20131007.","journal-title":"N Engl J Med"},{"key":"1516_CR8","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1182\/blood-2015-05-647925","volume":"126","author":"D Rossi","year":"2015","unstructured":"Rossi D, Terzi-Di-Bergamo L, De Paoli L, Cerri M, Ghilardi G, Chiarenza A, et al. Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. Blood. 2015;126:1921\u20134.","journal-title":"Blood."},{"key":"1516_CR9","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1158\/0008-5472.CAN-18-3962","volume":"79","author":"DC Hinshaw","year":"2019","unstructured":"Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates Cancer progression. Cancer Res. 2019;79:4557\u201366.","journal-title":"Cancer Res"},{"key":"1516_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","volume":"51","author":"FR Greten","year":"2019","unstructured":"Greten FR, Grivennikov SI. Inflammation and Cancer: triggers, mechanisms, and consequences. Immunity. 2019;51:27\u201341.","journal-title":"Immunity."},{"key":"1516_CR11","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41590-020-0620-x","volume":"21","author":"B Diskin","year":"2020","unstructured":"Diskin B, Adam S, Cassini MF, Sanchez G, Liria M, Aykut B, et al. PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer. Nat Immunol. 2020;21:442\u201354.","journal-title":"Nat Immunol"},{"key":"1516_CR12","doi-asserted-by":"publisher","first-page":"814","DOI":"10.4049\/jimmunol.1700755","volume":"201","author":"J Crespo","year":"2018","unstructured":"Crespo J, Wu K, Li W, Kryczek I, Maj T, Vatan L, et al. Human naive T cells express functional CXCL8 and promote tumorigenesis. J Immunol. 2018;201:814\u201320.","journal-title":"J Immunol"},{"key":"1516_CR13","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1158\/2159-8290.CD-19-0958","volume":"10","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Lazarus J, Steele NG, Yan W, Lee H-J, Nwosu ZC, et al. Regulatory T-cell depletion alters the tumor microenvironment and accelerates pancreatic carcinogenesis. Cancer Discov. 2020;10:422\u201339.","journal-title":"Cancer Discov."},{"key":"1516_CR14","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1126\/science.1082305","volume":"300","author":"DJ Shedlock","year":"2003","unstructured":"Shedlock DJ, Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science. 2003;300:337\u20139.","journal-title":"Science."},{"key":"1516_CR15","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1146\/annurev.immunol.23.021704.115825","volume":"24","author":"F Castellino","year":"2006","unstructured":"Castellino F, Germain RN. Cooperation between CD4+ and CD8+ T cells: when, where, and how. Annu Rev Immunol. 2006;24:519\u201340.","journal-title":"Annu Rev Immunol"},{"key":"1516_CR16","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.immuni.2018.01.007","volume":"48","author":"BV Kumar","year":"2018","unstructured":"Kumar BV, Connors TJ, Farber DL. Human T cell development, localization, and function throughout life. Immunity. 2018;48:202\u201313.","journal-title":"Immunity."},{"key":"1516_CR17","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1182\/blood-2012-09-457531","volume":"121","author":"JC Riches","year":"2013","unstructured":"Riches JC, Davies JK, Mcclanahan F, Fatah R, Iqbal S, Agrawal S, et al. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood. 2013;121:1612\u201321.","journal-title":"Blood."},{"key":"1516_CR18","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1172\/JCI24176","volume":"115","author":"G G\u00f6rg\u00fcn","year":"2005","unstructured":"G\u00f6rg\u00fcn G, TaW H, Zahrieh D, Neuberg D, Gribben JG. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest. 2005;115:1797\u2013805.","journal-title":"J Clin Invest"},{"key":"1516_CR19","doi-asserted-by":"publisher","first-page":"a008722","DOI":"10.1101\/cshperspect.a008722","volume":"5","author":"JM Hardwick","year":"2013","unstructured":"Hardwick JM, Soane L. Multiple functions of BCL-2 family proteins. Cold Spring Harb Perspect Biol. 2013;5:a008722.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"1516_CR20","doi-asserted-by":"publisher","first-page":"3950","DOI":"10.3390\/ijms19123950","volume":"19","author":"M Garc\u00eda-Aranda","year":"2018","unstructured":"Garc\u00eda-Aranda M, P\u00e9rez-Ruiz E, Redondo M. Bcl-2 inhibition to overcome resistance to chemo- and immunotherapy. Int J Mol Sci. 2018;19:3950.","journal-title":"Int J Mol Sci"},{"key":"1516_CR21","doi-asserted-by":"publisher","first-page":"938","DOI":"10.3390\/cancers12040938","volume":"12","author":"M Klanova","year":"2020","unstructured":"Klanova M, Klener P. BCL-2 proteins in pathogenesis and therapy of B-cell non-Hodgkin lymphomas. Cancers (Basel). 2020;12:938.","journal-title":"Cancers (Basel)"},{"key":"1516_CR22","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1189\/jlb.5A0416-194R","volume":"101","author":"A Goropev\u0161ek","year":"2017","unstructured":"Goropev\u0161ek A, Gorenjak M, Gradi\u0161nik S, Dai K, Holc I, Hojs R, et al. STAT5 phosphorylation in CD4 T cells from patients with SLE is related to changes in their subsets and follow-up disease severity. J Leukoc Biol. 2017;101:1405\u201318.","journal-title":"J Leukoc Biol"},{"key":"1516_CR23","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"AW Roberts","year":"2016","unstructured":"Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. Targeting BCL2 with Venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:311\u201322.","journal-title":"N Engl J Med"},{"key":"1516_CR24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD Dinardo","year":"2019","unstructured":"Dinardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133:7\u201317.","journal-title":"Blood."},{"key":"1516_CR25","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1182\/blood.2020009081","volume":"138","author":"J Lee","year":"2021","unstructured":"Lee J, Khan DH, Hurren R, Xu M, Na Y, Kang H, et al. Venetoclax enhances T cell-mediated anti-leukemic activity by increasing ROS production. Blood. 2021;138:234\u201345.","journal-title":"Blood."},{"key":"1516_CR26","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, D\u00f6hner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131:2745\u201360.","journal-title":"Blood."},{"key":"1516_CR27","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1084\/jem.20042276","volume":"201","author":"JC Marie","year":"2005","unstructured":"Marie JC, Letterio JJ, Gavin M, Rudensky AY. TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med. 2005;201:1061\u20137.","journal-title":"J Exp Med"},{"key":"1516_CR28","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1182\/blood-2007-07-098681","volume":"111","author":"A Majid","year":"2008","unstructured":"Majid A, Tsoulakis O, Walewska R, Gesk S, Siebert R, Kennedy DBJ, et al. BCL2 expression in chronic lymphocytic leukemia: lack of association with the BCL2 938A>C promoter single nucleotide polymorphism. Blood. 2008;111:874\u20137.","journal-title":"Blood."},{"key":"1516_CR29","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1182\/blood.V82.6.1820.1820","volume":"82","author":"M Hanada","year":"1993","unstructured":"Hanada M, Delia D, Aiello A, Stadtmauer E, Reed JC. Bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood. 1993;82:1820\u20138.","journal-title":"Blood."},{"key":"1516_CR30","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/s41419-020-03144-y","volume":"11","author":"I Kapoor","year":"2020","unstructured":"Kapoor I, Bodo J, Hill BT, Hsi ED, Almasan A. Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance. Cell Death Dis. 2020;11:941.","journal-title":"Cell Death Dis"},{"key":"1516_CR31","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1001\/jamaoncol.2021.1649","volume":"7","author":"N Jain","year":"2021","unstructured":"Jain N, Keating M, Thompson P, Ferrajoli A, Burger JA, Borthakur G, et al. Ibrutinib plus Venetoclax for first-line treatment of chronic lymphocytic leukemia: a nonrandomized phase 2 trial. JAMA Oncol. 2021;7:1213\u20139.","journal-title":"JAMA Oncol"},{"key":"1516_CR32","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.3324\/haematol.2020.261107","volume":"106","author":"S Stilgenbauer","year":"2021","unstructured":"Stilgenbauer S, Morschhauser F, Wendtner C-M, Cartron G, Hallek M, Eichhorst B, et al. Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase 1b study (GO28440). Haematologica. 2021;106:2834\u201344.","journal-title":"Haematologica."},{"key":"1516_CR33","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/nyas.12045","volume":"1285","author":"TT Renault","year":"2013","unstructured":"Renault TT, Chipuk JE. Getting away with murder: how does the BCL-2 family of proteins kill with immunity? Ann N Y Acad Sci. 2013;1285:59\u201379.","journal-title":"Ann N Y Acad Sci"},{"key":"1516_CR34","doi-asserted-by":"publisher","first-page":"7268","DOI":"10.1038\/s41467-021-27197-5","volume":"12","author":"ARM Almeida","year":"2021","unstructured":"Almeida ARM, Neto JL, Cachucho A, Euz\u00e9bio M, Meng X, Kim R, et al. Interleukin-7 receptor \u03b1 mutational activation can initiate precursor B-cell acute lymphoblastic leukemia. Nat Commun. 2021;12:7268.","journal-title":"Nat Commun"},{"key":"1516_CR35","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.ccell.2018.07.007","volume":"34","author":"M Vanden Bempt","year":"2018","unstructured":"Vanden Bempt M, Demeyer S, Broux M, De Bie J, Bornschein S, Mentens N, et al. Cooperative enhancer activation by TLX1 and STAT5 drives development of NUP214-ABL1\/TLX1-positive T cell acute lymphoblastic leukemia. Cancer Cell. 2018;34:271\u201385.","journal-title":"Cancer Cell"},{"key":"1516_CR36","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1007\/s00018-009-0026-2","volume":"66","author":"CJ Workman","year":"2009","unstructured":"Workman CJ, Szymczak-Workman AL, Collison LW, Pillai MR, DaA V. The development and function of regulatory T cells. Cell Mol Life Sci. 2009;66:2603\u201322.","journal-title":"Cell Mol Life Sci"},{"key":"1516_CR37","doi-asserted-by":"publisher","first-page":"5522","DOI":"10.1158\/0008-5472.CAN-09-0266","volume":"69","author":"Z-Z Yang","year":"2009","unstructured":"Yang Z-Z, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM. Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin's lymphoma. Cancer Res. 2009;69:5522\u201330.","journal-title":"Cancer Res"},{"key":"1516_CR38","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12967-018-1545-0","volume":"16","author":"S De Matteis","year":"2018","unstructured":"De Matteis S, Molinari C, Abbati G, Rossi T, Napolitano R, Ghetti M, et al. Immunosuppressive Treg cells acquire the phenotype of effector-T cells in chronic lymphocytic leukemia patients. J Transl Med. 2018;16:172.","journal-title":"J Transl Med"},{"key":"1516_CR39","first-page":"677","volume":"20","author":"K Giannopoulos","year":"2008","unstructured":"Giannopoulos K, Schmitt M, Kowal M, Wlasiuk P, Bojarska-Junak A, Chen J, et al. Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia. Oncol Rep. 2008;20:677\u201382.","journal-title":"Oncol Rep"},{"key":"1516_CR40","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/modpathol.2011.164","volume":"25","author":"A Biancotto","year":"2012","unstructured":"Biancotto A, Dagur PK, Fuchs JC, Wiestner A, Bagwell CB, Mccoy JP. Phenotypic complexity of T regulatory subsets in patients with B-chronic lymphocytic leukemia. Mod Pathol. 2012;25:246\u201359.","journal-title":"Mod Pathol"},{"key":"1516_CR41","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1182\/blood-2005-02-0642","volume":"106","author":"M Beyer","year":"2005","unstructured":"Beyer M, Kochanek M, Darabi K, Popov A, Jensen M, Endl E, et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood. 2005;106:2018\u201325.","journal-title":"Blood."},{"key":"1516_CR42","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S0145-2126(01)00194-1","volume":"26","author":"M Podhorecka","year":"2002","unstructured":"Podhorecka M, Dmoszynska A, Rolinski J, Wasik E. T type 1\/type 2 subsets balance in B-cell chronic lymphocytic leukemia--the three-color flow cytometry analysis. Leuk Res. 2002;26:657\u201360.","journal-title":"Leuk Res"},{"key":"1516_CR43","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1002\/cncr.25752","volume":"117","author":"L Weiss","year":"2011","unstructured":"Weiss L, Melchardt T, Egle A, Grabmer C, Greil R, Tinhofer I. Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia. Cancer. 2011;117:2163\u20139.","journal-title":"Cancer."},{"key":"1516_CR44","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1158\/2159-8290.CD-19-0759","volume":"11","author":"FJ Kohlhapp","year":"2021","unstructured":"Kohlhapp FJ, Haribhai D, Mathew R, Duggan R, Ellis PA, Wang R, et al. Venetoclax increases Intratumoral effector T cells and antitumor efficacy in combination with immune checkpoint blockade. Cancer Discov. 2021;11:68\u201379.","journal-title":"Cancer Discov"},{"key":"1516_CR45","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.it.2015.02.008","volume":"36","author":"KE Pauken","year":"2015","unstructured":"Pauken KE, Wherry EJ. Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 2015;36:265\u201376.","journal-title":"Trends Immunol"},{"key":"1516_CR46","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15:486\u201399.","journal-title":"Nat Rev Immunol."},{"key":"1516_CR47","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1126\/science.aaf0683","volume":"355","author":"AO Kamphorst","year":"2017","unstructured":"Kamphorst AO, Wieland A, Nasti T, Yang S, Zhang R, Barber DL, et al. Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science. 2017;355:1423\u20137.","journal-title":"Science."},{"key":"1516_CR48","doi-asserted-by":"publisher","first-page":"e000911","DOI":"10.1136\/jitc-2020-000911","volume":"8","author":"N Acharya","year":"2020","unstructured":"Acharya N, Sabatos-Peyton C, Anderson AC. Tim-3 finds its place in the cancer immunotherapy landscape. J Immunother Cancer. 2020;8:e000911.","journal-title":"J Immunother Cancer"},{"key":"1516_CR49","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1182\/blood-2012-02-411678","volume":"120","author":"AG Ramsay","year":"2012","unstructured":"Ramsay AG, Clear AJ, Fatah R, Gribben JG. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood. 2012;120:1412\u201321.","journal-title":"Blood."},{"key":"1516_CR50","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1182\/blood-2017-02-765685","volume":"129","author":"W Ding","year":"2017","unstructured":"Ding W, Laplant BR, Call TG, Parikh SA, Leis JF, He R, et al. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood. 2017;129:3419\u201327.","journal-title":"Blood."},{"key":"1516_CR51","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","volume":"35","author":"R Chen","year":"2017","unstructured":"Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, et al. Phase II study of the efficacy and safety of Pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma. J Clin Oncol. 2017;35:2125\u201332.","journal-title":"J Clin Oncol"},{"key":"1516_CR52","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1084\/jem.173.5.1099","volume":"173","author":"PJ Peters","year":"1991","unstructured":"Peters PJ, Borst J, Oorschot V, Fukuda M, Kr\u00e4henb\u00fchl O, Tschopp J, et al. Cytotoxic T lymphocyte granules are secretory lysosomes, containing both perforin and granzymes. J Exp Med. 1991;173:1099\u2013109.","journal-title":"J Exp Med"},{"key":"1516_CR53","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.4049\/jimmunol.174.4.2124","volume":"174","author":"PA Revell","year":"2005","unstructured":"Revell PA, Grossman WJ, Thomas DA, Cao X, Behl R, Ratner JA, et al. Granzyme B and the downstream granzymes C and\/or F are important for cytotoxic lymphocyte functions. J Immunol. 2005;174:2124\u201331.","journal-title":"J Immunol"},{"key":"1516_CR54","doi-asserted-by":"crossref","unstructured":"Voskoboinik I, Whisstock JC, Trapani JA. Perforin and granzymes: function, dysfunction and human pathology 2015;15:388\u2013400.","DOI":"10.1038\/nri3839"},{"key":"1516_CR55","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41577-019-0223-7","volume":"20","author":"A Kallies","year":"2019","unstructured":"Kallies A, Zehn D, Utzschneider DT. Precursor exhausted T cells: key to successful immunotherapy? Nat Rev Immunol. 2019;20:128\u201336.","journal-title":"Nat Rev Immunol"},{"key":"1516_CR56","doi-asserted-by":"crossref","unstructured":"Mahnke YD, Brodie TM, Sallusto F, Roederer M, Lugli E. The who\u2019s who of T-cell differentiation: human memory T-cell subsets 2013;43:2797\u20132809.","DOI":"10.1002\/eji.201343751"},{"key":"1516_CR57","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3390\/cancers8030036","volume":"8","author":"V Golubovskaya","year":"2016","unstructured":"Golubovskaya V, Wu L. Different subsets of T cells, memory, effector functions, and CAR-T immunotherapy. Cancers (Basel). 2016;8:36.","journal-title":"Cancers (Basel)."},{"key":"1516_CR58","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.3109\/10428194.2012.673224","volume":"53","author":"SH Tonino","year":"2012","unstructured":"Tonino SH, Van De Berg PJ, Yong SL, Ten Berge IJ, Kersten MJ, RaW VL, et al. Expansion of effector T cells associated with decreased PD-1 expression in patients with indolent B cell lymphomas and chronic lymphocytic leukemia. Leuk Lymphoma. 2012;53:1785\u201394.","journal-title":"Leuk Lymphoma"},{"key":"1516_CR59","first-page":"2427","volume":"118","author":"AG Ramsay","year":"2008","unstructured":"Ramsay AG, Johnson AJ, Lee AM, Gorg\u00fcn G, Le Dieu R, Blum W, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest. 2008;118:2427\u201337.","journal-title":"J Clin Invest"},{"key":"1516_CR60","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1182\/blood-2003-01-0182","volume":"102","author":"WJM Mackus","year":"2003","unstructured":"Mackus WJM, Frakking FNJ, Grummels A, Gamadia LE, De Bree GJ, Hamann D, et al. Expansion of CMV-specific CD8+CD45RA+CD27- T cells in B-cell chronic lymphocytic leukemia. Blood. 2003;102:1057\u201363.","journal-title":"Blood."},{"key":"1516_CR61","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1182\/blood-2013-08-518183","volume":"123","author":"GD Te Raa","year":"2014","unstructured":"Te Raa GD, Pascutti MF, Garc\u00eda-Vallejo JJ, Reinen E, Remmerswaal EBM, Ten Berge IJM, et al. CMV-specific CD8+ T-cell function is not impaired in chronic lymphocytic leukemia. Blood. 2014;123:717\u201324.","journal-title":"Blood."},{"key":"1516_CR62","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1182\/blood-2019-01-896290","volume":"133","author":"IW Flinn","year":"2019","unstructured":"Flinn IW, Gribben JG, Dyer MJS, Wierda W, Maris MB, Furman RR, et al. Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed\/refractory chronic lymphocytic leukemia. Blood. 2019;133:2765\u201375.","journal-title":"Blood"},{"key":"1516_CR63","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","volume":"378","author":"JF Seymour","year":"2018","unstructured":"Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D\u2019rozario J, Assouline S, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378:1107\u201320.","journal-title":"N Engl J Med"},{"key":"1516_CR64","doi-asserted-by":"publisher","first-page":"3704","DOI":"10.1182\/blood-2018-99-113134","volume":"132","author":"R Mathew","year":"2018","unstructured":"Mathew R, Haribhai D, Kohlhapp F, Duggan R, Ellis P, Riehm JJ, et al. The BCL-2-selective inhibitor Venetoclax spares activated T-cells during anti-tumor immunity. Blood. 2018;132:3704.","journal-title":"Blood."}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-022-01516-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-022-01516-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-022-01516-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T12:03:39Z","timestamp":1674821019000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-022-01516-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,22]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1516"],"URL":"https:\/\/doi.org\/10.1186\/s12943-022-01516-w","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,22]]},"assertion":[{"value":"30 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the Jiangsu Province Hospital (2018-SRFA-087), and written informed consent was obtained from all patients according to the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"59"}}